Skip to main contentLast updated: 17-Nov-2026
Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Stomach Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience
In short
GIST care mixes an operation with a targeted tablet, imatinib. A tumour that can be removed safely is operated on first. A large or awkward one often gets tablets first.
After full removal, tablets are for higher-risk tumours, usually for three years. If the GIST has spread, tablets come first and carry on while they work.
One team plans the whole path before the first step, so that an early choice does not shut off a later one.
For the whole story of GIST, from the first test to imatinib and surgery, read our GIST treatment in Ahmedabad page. This post explains how the operation and the tablets are put in order.
Three things decide it: how far the tumour has reached, which gene change drives it, and how likely it is to return. Your team checks all three first.
This is why a gene report and a good scan are asked for before any decision. Our post on how a GIST is confirmed with CT, scope and biopsy explains what is sent and when.
The first step follows the situation. Removal comes first when it is safe and complete. Tablets come first when removal is risky, or when the disease has spread.
| Situation | Usual first step | What follows |
|---|---|---|
| Tumour can be removed fully and safely | Operation | Tablets for three years if the risk is high and the gene type responds |
| Large, or touching other organs, or removal would take much more than the tumour | Imatinib for several months | Scans, then the operation at the right moment, then tablets again |
| Tumour in the low rectum, the food-pipe junction or the duodenum | Imatinib, so that a smaller operation may do | A limited removal where possible, then tablets by risk |
| Spread to the liver or belly lining at diagnosis | Imatinib, started after the biopsy and gene report | Tablets continue; an operation only for chosen patients |
| PDGFRA D842V gene change | Operation if removable; imatinib is not used | A different tablet, avapritinib, if the disease needs medicine |
Please read the table as a guide, not a rule. Two tumours of the same size can need different orders because their gene change or position differs.
When the whole tumour can be taken out in one piece, surgery comes first. A tumour that bursts during the operation is more likely to return, so it is handled with care.
The tumour is then studied under the microscope for size, the number of dividing cells and the site. These set the risk group, which settles the tablets. Our post on how common GIST is and what types exist explains how these groups are formed.
Imatinib can shrink a large tumour so that it comes out cleanly with a smaller operation. It is used when operating first would be risky or incomplete.
The gene report must come first. Imatinib is of no use against a PDGFRA D842V change, and giving it only delays the right treatment.
Usually six to nine months, until two scans a few weeks apart show no further change. The aim is to operate at that plateau, not at the first shrinkage.
Going on past the plateau does not shrink the tumour further. It gives the tumour time to learn a new trick, a second gene change that makes the tablet fail. So the operation is not put off for a longer wait.
Only patients whose tumour is likely to return and whose gene type responds to imatinib. Three years is usual, and a few at the highest risk may be offered longer.
Returns are most likely in the months after the tablets stop. That is why the length is fixed with care, and why scans stay closer together at that time.
Then imatinib starts the plan and goes on for as long as it controls the disease. Stopping it, even when the scan looks clear, usually lets the tumour grow again.
Removing a tumour while it is actively growing on the tablet does not help. It is better to change the medicine in that case.
The next medicines follow in a set order: a higher imatinib dose where it applies, then sunitinib, regorafenib and ripretinib. Each was tested after the one before it failed.
Skipping the order loses benefit. A later medicine given too early cannot be given again with the same value.
A team does, because each step touches the next. A surgeon, a cancer physician, a radiologist and a pathologist look at your reports together before any step is taken.
The team meets again at each turn. These are before tablets start, before the operation, after it and when the tablets are due to stop. The evidence behind these steps is set out in our post on the key GIST studies.
No. A tumour that can be removed whole and safely is operated on first. A large one, or one that would need a bigger operation, often gets imatinib first to shrink it.
Often yes. Imatinib for several months can shrink it so that it comes out cleanly. Sometimes the operation is smaller than it would have been at the start.
Usually yes. Tablets seldom clear a GIST completely, and the part that is left can grow again. The operation removes it, and the tablets are restarted afterwards.
Only for a short time, as your team advises, and it is started again soon after you are eating. Do not stop or change the dose on your own.
This gene change does not respond to imatinib. Giving it would only delay the right treatment. Surgery is used if the tumour is removable, and a different medicine, avapritinib, if medicine is needed.
Sometimes. It is kept for patients whose disease has responded to tablets and stayed steady for months. Nearly all of it must be removable. For most, tablets are the main treatment.
Studies show that returns mostly follow stopping. The tablets hold the tumour back while they are taken. So the length of treatment is set with care by your risk group.
For the full picture of GIST and its treatment, start at the GIST treatment in Ahmedabad page. For questions before you travel, call +91-63555-64601.
Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601
Told you have a GIST and unsure whether the operation or the tablets come first? The order is not the same for everyone. It depends on where the tumour sits, how big it is, whether it has spread and what your gene report shows. Dr Harsh Shah, a stomach cancer surgeon in Ahmedabad, will set the order from your own reports. Bring your scans, biopsy report and gene report. You can call us or book by message. Call For Appointment Book on WhatsApp Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.
Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.